share_log

Chardan Capital Initiates Coverage On Anixa Biosciences With Buy Rating, Announces Price Target of $8

Benzinga Real-time News ·  Dec 23, 2022 05:41

Chardan Capital analyst Matthew Barcus initiates coverage on Anixa Biosciences (NASDAQ:ANIX) with a Buy rating and announces Price Target of $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment